Last reviewed · How we verify

Grass pollen specific immunotherapy

Allergopharma GmbH & Co. KG · Phase 3 active Small molecule

Grass pollen specific immunotherapy desensitizes the immune system to grass pollen allergens by gradually introducing increasing doses to induce immune tolerance.

Grass pollen specific immunotherapy desensitizes the immune system to grass pollen allergens by gradually introducing increasing doses to induce immune tolerance. Used for Grass pollen-induced allergic rhinitis and/or allergic asthma.

At a glance

Generic nameGrass pollen specific immunotherapy
SponsorAllergopharma GmbH & Co. KG
Drug classAllergen immunotherapy
ModalitySmall molecule
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

This immunotherapy works by administering gradually increasing doses of grass pollen extract to shift the immune response from IgE-mediated allergic reactions toward protective IgG and regulatory T cell responses. Over time, this process reduces allergic sensitivity and clinical symptoms upon natural grass pollen exposure. The mechanism involves both central tolerance induction and peripheral immune regulation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results